24×7 Emergency Care

1-8-31/1, Minister Road, Secunderabad, Telangana 500003

Conditions

EPILEPSY AND SEIZURE DISORDERS

Medical Refractory Epilepsy in Hyderabad — When Medications Have Not Controlled Your Seizures

Medical refractory epilepsy — also called drug-resistant epilepsy (DRE) or intractable epilepsy — is defined by the International League Against Epilepsy (ILAE) as the failure of adequate trials of two or more appropriate antiepileptic drugs, used alone or in combination at tolerated doses, to achieve sustained seizure freedom. Approximately 30–40% of all people with epilepsy have drug-resistant epilepsy. For many, epilepsy surgery is the most effective available treatment — offering seizure freedom in 60–80% of carefully selected candidates.

View Our Specialists

Medical term

Drug-resistant epilepsy (DRE) · intractable epilepsy · pharmacoresistant epilepsy — all synonyms for the same condition.

ILAE definition

Failure of two appropriate antiepileptic drugs at adequate doses — whether alone or in combination.

How common

30–40% of all epilepsy patients. Approximately 3.5 million people in India have drug-resistant epilepsy.

Main causes

Hippocampal sclerosis · focal cortical dysplasia (FCD) · low-grade tumour (DNET, ganglioglioma) · cavernous malformation · genetic epilepsy syndrome.

Surgical success rate

65–80% seizure-free (Engel Class I) after temporal lobectomy for hippocampal sclerosis. Evidence: Wiebe NEJM 2001 RCT.

When to refer for surgery

Immediately after the second drug fails — not after 5, 10, or 20 years. Earlier surgery produces better cognitive outcomes.

KIMS programme

Video-EEG monitoring unit · sEEG with Stealth AutoGuide robotic guidance · Dr. Sita Jayalakshmi (neurology) · Senior Consultant, Neurosurgery.

Department

Epilepsy Surgery · Neurology · Neurosurgery

Appointment

040-44885000

Emergency Notice

About This Condition

When to Call Immediately

⚠ EMERGENCY: A seizure lasting more than 5 minutes · a second seizure with no recovery in between · any seizure with no breathing or blue lips: call 040-46324365 immediately. This is status epilepticus — a medical emergency.

Definition

Medical Refractory Epilepsy

Book Epilepsy Consultation

Expert epilepsy diagnosis and surgical evaluation at KIMS Neuroscience Hyderabad.

040-44885000International enquiries neuroscience@kimshospitals.com

Clinical Definition

What is Medical Refractory Epilepsy?

1.1 Simple Explanation

Epilepsy is a condition in which the brain’s electrical system produces sudden, abnormal bursts of activity that cause seizures. For most people with epilepsy, the right antiepileptic medication stops the seizures. For approximately one in three, it does not — no matter how many medications are tried, at whatever doses, in whatever combinations. This is medical refractory epilepsy.

The word “refractory” comes from the Latin for “resisting treatment.” It does not mean untreatable. It means that antiepileptic drugs alone are not sufficient — and that other interventions, including epilepsy surgery, vagus nerve stimulation, deep brain stimulation, or dietary therapy, need to be considered. The tragedy of refractory epilepsy in India is not that it cannot be treated — it is that most patients who could benefit from surgery are never referred for evaluation.

At KIMS Hyderabad, the comprehensive epilepsy programme provides the full evaluation-to-treatment pathway for patients across Telangana and Andhra Pradesh whose seizures have not responded to medication.

1.2 Why Seizures Become Drug-Resistant

Pharmacokinetic resistance

Some patients’ bodies metabolise antiepileptic drugs faster than normal, so drug levels in the blood never reach therapeutic concentrations in the brain. P-glycoprotein overexpression in the blood-brain barrier actively pumps certain drugs out of the brain before they can work. This is a biological mechanism, not a compliance problem.

Pharmacodynamic resistance

Sodium channels — the target of drugs like carbamazepine and lamotrigine — can mutate in the epileptogenic zone so that the drugs no longer block them effectively. Adequate drug levels are present; the seizures continue because the target has changed.

A fixed structural cause that drugs cannot address

Many refractory cases are caused by a structural abnormality: hippocampal sclerosis, focal cortical dysplasia, a low-grade tumour, or a cavernous malformation. Drugs suppress seizures globally but cannot correct the specific structural lesion generating them. Surgery to remove the lesion is the only curative intervention for these cases.

1.3 Classification — Types of Refractory Epilepsy

Medical refractory epilepsy is a functional category applied across many underlying epilepsy syndromes. The most clinically important distinction is:

Type	Definition	Surgical Outcome	Most Common Cause
Lesional DRE	Structural lesion visible on MRI and corresponds to seizure onset zone	Best outcomes: 65–85% seizure freedom	Hippocampal sclerosis · FCD · low-grade tumour · cavernoma
MRI-negative DRE	MRI appears normal · requires advanced evaluation	50–70% seizure freedom with full evaluation	Subtle FCD below MRI resolution · genetic causes
Temporal lobe epilepsy	Most common surgically treatable type	65–80% seizure freedom after temporal lobectomy	Mesial temporal sclerosis (hippocampal sclerosis)
Extratemporal epilepsy	Frontal, parietal, or occipital lobe onset	40–75% depending on lesion type	FCD · post-traumatic scar · cavernoma
Generalised DRE	Whole-brain onset · not typically resectable	Neuromodulation (VNS, DBS, CC) · no curative surgery	Lennox-Gastaut · Dravet syndrome · genetic epilepsies

Medical refractory epilepsy is defined by two failed drug trials — not ten, not twenty. At that point, surgical evaluation is the clinically correct next step, and it offers seizure freedom in 65–80% of selected candidates.

Clinical Recognition

Symptoms and Early Warning Signs

2.1 Recognising That Epilepsy Has Become Refractory

Medical refractory epilepsy is not a sudden new symptom — it is a pattern that develops over time. The moment to recognise it and act is when two appropriate medications at adequate doses have failed to stop the seizures. Many patients and families accept continued seizures as “just how epilepsy is” for years, missing the window when surgical intervention is most effective.

The two-drug threshold — the critical recognition point

The ILAE definition is specific: two adequately trialled drugs, not two total drugs. A drug is adequately trialled if it is appropriate for the seizure type, taken at a therapeutic dose, taken for a sufficient duration, and stopped for clear reasons of failure (continued seizures) rather than side effects alone.

2.2 Seizure Types in Refractory Epilepsy

Focal onset impaired awareness seizures

The patient stops, stares, does not respond, and may make repetitive automatic movements (lip-smacking, hand-picking, chewing). Lasts 1–2 minutes, followed by confusion. No memory of the episode. Most common in temporal lobe epilepsy. Can occur multiple times per week.

Focal to bilateral tonic-clonic seizures

A focal seizure that spreads to both hemispheres: body stiffens (tonic), then jerks rhythmically (clonic). Loss of consciousness, possible tongue bite, bladder incontinence. Highest SUDEP risk and highest injury risk. Carries the most immediate daily danger.

Focal aware seizures (aura)

Patient remains conscious during the seizure. Content reflects the focus location: temporal → rising epigastric sensation, fear, déjà vu · motor focus → rhythmic limb jerking · occipital → flashing lights. Often the warning sign before a larger seizure.

Drop attacks (atonic seizures)

Sudden loss of muscle tone causing an instant, unprotected fall to the ground. No warning. No loss of consciousness. Lasts 1–2 seconds. Characteristic of Lennox-Gastaut syndrome. Repeated head injuries are the primary physical consequence.

2.3 The Cumulative Burden of Refractory Epilepsy

Medical refractory epilepsy causes harm not only through the seizures themselves but through cumulative neurological, cognitive, psychosocial, and safety consequences:

• SUDEP risk: Approximately 1 in 1,000 patient-years in refractory epilepsy — significantly higher than in controlled epilepsy.

• Cognitive decline: Repeated tonic-clonic seizures cause progressive hippocampal atrophy. The longer refractory epilepsy goes untreated, the less function there is to preserve.

• Driving prohibition: Active seizures legally prohibit driving in India. Refractory epilepsy permanently restricts independence and livelihood for working-age patients.

• Employment and education: Unpredictable seizures make sustained employment and academic completion extremely difficult for most patients with refractory epilepsy.

• Medication burden: 3–4 concurrent antiepileptic drugs cause fatigue, cognitive slowing, mood changes, liver toxicity, and teratogenicity in women of childbearing age.

• Psychosocial disability: Depression affects 30–40% of refractory epilepsy patients — two to four times the general population rate.

The average time from epilepsy onset to epilepsy surgery in India is 15–20 years. In well-functioning international centres, it is 5–8 years. The gap represents avoidable cumulative harm.

Refractory epilepsy causes harm not only through seizures but through progressive cognitive decline, SUDEP risk, and lost independence — every year without evaluation adds to this damage and cannot be recovered.

Evaluation Pathway

Diagnosis at KIMS

How We Diagnose Medical Refractory Epilepsy at KIMS

3.1 Confirming Drug Resistance

Before surgical evaluation begins, the KIMS epilepsy team confirms that the patient truly has drug-resistant epilepsy — and that the events are epileptic rather than psychogenic non-epileptic attacks (PNEA), which affect approximately 20–30% of patients referred with apparent drug-resistant epilepsy and require a completely different management approach.

Are the seizures truly epileptic?

Psychogenic non-epileptic attacks (PNEA) can appear identical to epileptic seizures. The only reliable way to distinguish them is long-term video-EEG monitoring, in which a captured event is correlated with simultaneously recorded EEG. PNEA produce no EEG change during the event.

Have the drugs truly been adequately trialled?

Drug resistance is defined by failure of two adequate trials. The KIMS team reviews which drugs were used, at what doses, whether drug levels were measured, and whether the drugs chosen were appropriate for the specific seizure type.

3.2 Phase 1 Evaluation — Non-Invasive

Long-Term Video-EEG Monitoring

Admitted to the KIMS Epilepsy Monitoring Unit for 5–10 days. Medications gradually reduced to provoke habitual seizures. Each seizure recorded simultaneously on video and EEG. Confirms that events are epileptic · characterises seizure semiology · EEG-localises the ictal onset zone. KIMS has three continuous long-term telemetry video-EEG units.

MRI Brain — Epilepsy Protocol (3 Tesla)

1 mm isotropic T1 MPRAGE · FLAIR and T2 coronal cuts perpendicular to hippocampus · SWI / susceptibility-weighted imaging · DWI. Read by a neuroradiologist with epilepsy imaging expertise. MRI-negative epilepsy (20–30% of cases) requires the full evaluation pathway.

FDG-PET (Positron Emission Tomography)

Measures glucose metabolism. The seizure onset zone shows reduced metabolism in the interictal state. Particularly valuable in MRI-negative epilepsy where the focus may not be visible on structural MRI. SISCOM provides complementary perfusion data.

Neuropsychological Assessment

Verbal and non-verbal memory · language lateralisation · attention, processing speed, executive function. Serves two purposes: predicts post-operative cognitive risk (verbal memory after dominant temporal surgery) and establishes a pre-operative baseline for comparison.

Multidisciplinary Epilepsy Surgery Conference

All Phase 1 data reviewed by: Dr. Sita Jayalakshmi (epilepsy neurology) · Senior Consultant, Neurosurgery (epilepsy surgery) · neuroradiologist · neuropsychologist. Decides: proceed to surgery (concordant focus identified) or proceed to Phase 2 invasive EEG.

3.3 Phase 2 — Invasive EEG Where Required

Stereoelectroencephalography (sEEG) — robotic guidance at KIMS

sEEG implants 8–15+ depth electrodes through small skull burr holes to record directly from specific cortical and subcortical targets. Patient monitored for 1–2 weeks capturing spontaneous seizures from depth electrodes. Provides millimetre-resolution localisation of the seizure onset zone. At KIMS, sEEG is performed using the Stealth AutoGuide™ robotic cranial guidance platform — the first in India — for precise electrode placement at each planned trajectory. Can sample deep structures (hippocampus, insula, orbitofrontal cortex, thalamus) that surface grids cannot reach.

3.4 Evaluation Decision Table

Phase 1 Finding	Implication	Next Step
MRI lesion + concordant EEG	Seizure focus confidently identified	Proceed directly to resective surgery
MRI lesion + discordant EEG	Lesion may not be the sole focus	Phase 2 sEEG to confirm · then surgery if confirmed
MRI negative + focal EEG + focal PET	Focus likely in hypometabolic region	Phase 2 sEEG to define · FCD likely on histology
MRI negative + non-focal EEG	No focal evidence from Phase 1	Phase 2 sEEG required · or consider neuromodulation
Generalised EEG + no focal semiology	Generalised epilepsy — not resectable	Corpus callosotomy (drops) · VNS · DBS · dietary therapy
Events without EEG change	PNEA confirmed — not drug-resistant epilepsy	Psychiatric assessment · CBT · not a surgical candidate

The KIMS evaluation answers one clinical question: does this patient have a seizure focus that can be safely removed? Phase 1 answers this non-invasively; Phase 2 sEEG answers it definitively when Phase 1 is inconclusive. Many patients told surgery is “not possible” have never had Phase 2 evaluation.

Treatment Options

Treatment

Treatment Options for Medical Refractory Epilepsy at KIMS

The treatment of medical refractory epilepsy at KIMS covers the full spectrum: resective surgery, disconnective surgery, Gamma Knife, neuromodulation, and dietary therapy. The recommendation for each patient is made by the multidisciplinary epilepsy conference based on seizure type, focus location, and individual circumstances.

60–80%

Seizure-Free Rate (Temporal Lobe)

3.5M+

Drug-Resistant Epilepsy Patients in India

4.1 Resective Surgery — Removing the Seizure Source

Temporal lobectomy — the most evidence-based epilepsy surgery

Removes the anterior temporal lobe including the hippocampus, amygdala, and parahippocampal gyrus on the side of the seizure focus. The landmark NEJM trial (Wiebe et al., 2001) demonstrated 64% seizure freedom at 1 year with surgery versus 8% with continued medical therapy. At KIMS, temporal lobectomy achieves Engel Class I (seizure freedom) in 65–80% of patients with hippocampal sclerosis. Surgery: 2–3 hours. Hospital stay: 5–7 days.

Selective amygdalohippocampectomy (SAH)

For strictly mesial temporal seizure onset: removes only the hippocampus and amygdala, preserving the lateral temporal neocortex. Equivalent seizure-free rates to temporal lobectomy with better preservation of lateral temporal cortex function. Choice between temporal lobectomy and SAH guided by intraoperative ECoG.

Lesionectomy — for visible structural causes

Surgical resection of the lesion (FCD, DNET, ganglioglioma, cavernoma) and surrounding epileptogenic cortex. Achieves seizure freedom in 50–85% depending on completeness of resection and histopathology. Performed across all brain regions including eloquent cortex, using neuronavigation, awake craniotomy, intraoperative ECoG, and continuous neurophysiological monitoring.

Extratemporal cortical resection — frontal, parietal, and occipital lobe

More challenging than temporal lobe surgery because seizure onset often involves eloquent cortex. Phase 2 sEEG is more commonly required. When a resectable focus is identified, surgery achieves seizure freedom in 40–75%. Intraoperative brain mapping used for all operations near eloquent cortex at KIMS.

4.2 Disconnective Surgery

Corpus callosotomy — for generalised drop attacks

Divides the corpus callosum, preventing seizures from spreading bilaterally. Does not eliminate seizures but reduces severity: primary indication is atonic seizures (drop attacks) causing repeated head injuries, most commonly in Lennox-Gastaut syndrome. Reduces drop attacks in 70–85% of patients. KIMS performs anterior two-thirds callosotomy as the standard approach.

Hemispherotomy — for catastrophic unilateral hemispheric epilepsy

Functional disconnection of one hemisphere. Used for Rasmussen encephalitis, hemimegalencephaly, or large perinatal porencephaly. Achieves 70–85% seizure freedom. Appropriate only when the affected hemisphere is already non-functional (severe established hemiplegia). KIMS performs the modified lateral approach that reduces operative blood loss.

Posterior Disconnection — for posterior quadrant epilepsy

Posterior disconnection (also called posterior quadrant disconnection or posterior quadrantotomy) is a surgical procedure in which the posterior cerebral cortex — the occipital lobe, posterior parietal lobe, and posterior temporal lobe — is functionally disconnected from the anterior brain by dividing the white matter tracts, the posterior corpus callosum, and the thalamo-cortical connections supplying the posterior quadrant. Unlike resection, the cortex is not removed but is rendered electrically isolated from the seizure-propagating circuitry of the rest of the brain.

Indication: Posterior quadrant epilepsy — seizures arising from the occipital lobe, parieto-occipital junction, or posterior temporal regions — where the epileptogenic zone is too extensive for localised resection, but where the posterior cortex is already functionally compromised. In most candidates, a fixed contralateral visual field defect (homonymous hemianopia) is already present from the underlying epilepsy or pathology, meaning the expected visual consequence of the surgery does not add functional loss.

Common underlying pathology: Posterior cortical dysplasia (focal cortical dysplasia Type II in the occipital or parieto-occipital region) · Sturge-Weber syndrome with posterior-predominant leptomeningeal angiomatosis · Hemimegalencephaly with predominant posterior involvement · Posterior perinatal infarct or porencephaly · Posterior-predominant Rasmussen encephalitis.

How it differs from hemispherotomy: Hemispherotomy disconnects the entire hemisphere. Posterior disconnection disconnects only the posterior quadrant, preserving motor and language cortex in the anterior hemisphere. It is the appropriate choice when seizure onset is confined to the posterior quadrant and the anterior (frontal and sensorimotor) cortex is functioning normally and generating no seizures.

Surgical outcomes: Published series report seizure freedom (Engel Class I) in approximately 60–75% of patients. Outcomes are best when pre-surgical evaluation with sEEG has confirmed posterior quadrant onset and when the underlying pathology is a well-circumscribed cortical dysplasia or vascular malformation. KIMS performs posterior disconnection using the modified lateral approach, with intraoperative neurophysiological monitoring to protect the motor strip boundary.

Expected deficits: Contralateral homonymous hemianopia — loss of the visual field on the side opposite the surgery. This is an expected and accepted consequence of the procedure, and in most candidates is already established before surgery. Motor function is preserved because the motor strip is not involved. Language function is preserved when the dominant hemisphere's posterior language cortex is not part of the disconnection (guided by pre-operative fMRI and sEEG language mapping).

4.3 Gamma Knife for Refractory Epilepsy

Gamma Knife for mesial temporal lobe epilepsy

For patients who refuse open surgery or are at elevated surgical risk. Seizure-free rates: approximately 50–65% at 2–3 years — lower than surgical temporal lobectomy, but without open surgery recovery burden. Radiation effect develops over 6–24 months. Available at KIMS.

Gamma Knife for epilepsy-associated lesions

For cavernous malformations, low-grade tumours, and cortical dysplasias in surgically inaccessible or high-risk locations. Considered case-by-case when resection carries unacceptable risk.

4.4 Neuromodulation — When Surgery is Not Appropriate

Vagus Nerve Stimulation (VNS)

Implantable device: pulse generator under the left clavicle, connected to the left vagus nerve. Delivers intermittent stimulation that modulates cortical excitability. Reduces seizure frequency by ≥50% in approximately 50–60% of patients, improving over 5+ years. Magnet mode can abort or shorten a seizure on activation. Appropriate when no resectable focus exists or resection was unsuccessful.

Deep Brain Stimulation (DBS) for refractory epilepsy

Bilateral DBS of the anterior nucleus of the thalamus (ANT-DBS). The SANTE trial (2010) demonstrated 69% seizure reduction at 2 years. Responsive neurostimulation (RNS) — a closed-loop system that detects and responds to seizure onset — is an emerging option for patients with a well-localised but unresectable focus. Both available at KIMS.

4.5 Dietary Therapy

Ketogenic diet (KD)

High-fat, very low-carbohydrate diet producing ketone bodies with anticonvulsant effect. Reduces seizures by ≥50% in approximately 50% of drug-resistant patients. Most effective in: Dravet syndrome, Lennox-Gastaut syndrome, GLUT-1 deficiency, pyruvate dehydrogenase deficiency. Medically supervised at KIMS. Requires regular blood and urine monitoring.

Modified Atkins Diet and Low Glycaemic Index Treatment

Less restrictive alternatives for patients who cannot maintain the classical KD. Comparable efficacy for adolescents and adults. Modified Atkins Diet allows up to 15–20g carbohydrate per day versus the classical KD’s near-zero carbohydrate threshold.

4.6 Antiepileptic Drug Review at KIMS

Medication review before surgical evaluation

Many patients labelled “treatment-resistant” are on inappropriate drugs for their seizure type · some have never had drug level measurement · rational polytherapy (combining drugs with complementary mechanisms) has not been attempted. A formal medication review by Dr. Sita Jayalakshmi is the first clinical action for every patient referred for surgical evaluation at KIMS.

Seven treatment options are available at KIMS for drug-resistant epilepsy — from surgery that cures to neuromodulation that controls. The right choice depends on seizure type, focus location, and individual evaluation, not on which option is most familiar to the referring physician.

Outcomes and Follow-Up

Expected Outcomes and Follow-Up

5.1 Surgical Outcomes — The Evidence

Surgery Type	Engel Class I (Seizure-Free)	Patient Group	Evidence Level
Temporal lobectomy (hippocampal sclerosis)	65–80% at 1 year · 55–70% at 5 years	TLE with MRI-confirmed hippocampal sclerosis	Class I · NEJM RCT (Wiebe 2001)
Temporal lobectomy (tumour/FCD)	70–85% at 2 years	Low-grade tumour or cortical dysplasia	Class II–III
Lesionectomy (extratemporal)	50–75% at 2 years	FCD · ganglioglioma · cavernoma	Class II
Hemispherotomy	70–85% at 2 years	Catastrophic unilateral hemispheric epilepsy	Class II–III
Posterior Disconnection	60–75% at 2 years	Posterior quadrant epilepsy (occipital/parieto-occipital onset) with established/expected visual field defect	Class II–III
Corpus callosotomy	70–85% drop attack reduction	Lennox-Gastaut · drop attacks	Class II
VNS	50–60% achieve ≥50% reduction	Non-resectable DRE	Class II RCT
ANT-DBS	69% seizure reduction at 2 years (SANTE trial)	Focal DRE · non-resectable	Class I RCT
Ketogenic diet	50% achieve ≥50% reduction · 5–10% seizure-free	DRE generalised epilepsy	Class II RCT

5.2 What Seizure Freedom Means

Driving — the most transformative milestone

One year of confirmed seizure freedom after surgery, verified by the epileptologist, makes the patient eligible to apply for a driving licence in India. For a patient who had seizures for 10–20 years, regaining the ability to drive is often described as the single most life-changing outcome of surgery.

Employment and education

Seizure freedom removes the primary barrier to sustained professional and academic life. Many patients return to employment or complete education within 12–18 months of successful surgery.

Medication reduction

By 2–3 years after surgery, approximately 30–40% of seizure-free patients are completely off antiepileptic medication. This eliminates years of side effects, costs, and teratogenic risk for women planning pregnancy.

Cognitive and psychological improvement

Measurable improvements in attention, memory, mood, and quality of life occur in the majority of seizure-free patients within the first year of surgery — independent of any cognitive effect from the surgery itself.

5.3 Follow-Up Protocol at KIMS

Post-operative monitoring schedule

Clinical review at 6 weeks, 3 months, 6 months, and 12 months · EEG at 3 and 12 months · MRI at 3 months and 12 months · Neuropsychological re-assessment at 12 months · Antiepileptic drug tapering begins at 12 months of seizure freedom.

Anti-seizure medication tapering protocol

One drug reduced at a time, at 25% of dose per 3 months, with close clinical monitoring. If seizures recur during tapering, the drug is increased back to the last effective dose. Complete drug freedom achieved in approximately 30–40% of seizure-free patients by year 3.

Telemedicine follow-up for outstation patients

For patients from Vijayawada, Nellore, Karimnagar, and other AP/Telangana cities: 3-month MRI and EEG performed locally, images sent to KIMS electronically · video consultations with the neurology team for routine reviews · annual in-person assessments at KIMS. Call 040-44885000 to arrange.

Epilepsy surgery at KIMS achieves seizure freedom in 65–80% of temporal lobe cases. Seizure freedom means driving, working, and living without the constant anticipation of the next seizure — outcomes that no antiepileptic drug has achieved for these patients.

Related Conditions

Explore related epilepsy and seizure disorders at KIMS Neuroscience:

Temporal Lobe Epilepsy Rasmussen Encephalitis Status Epilepticus Epilepsy and Seizure Disorders

Common Questions

FAQs

Patient FAQs About Medical Refractory Epilepsy

The following questions are structured for Google People Also Ask and AI Overview extraction. Each begins with a direct declarative answer before providing supporting detail.

No. There is almost certainly more that can be done — but it requires a different type of evaluation than general neurology can provide. The statement “there is nothing more to do” typically means “there are no more medications to try” — which is not the same thing. A comprehensive epilepsy surgery evaluation — video-EEG, high-resolution epilepsy-protocol MRI, PET, and neuropsychological assessment — determines whether your daughter’s seizures come from a specific, identifiable location in the brain that can be safely removed or treated. At KIMS, patients who were told exactly this have gone on to have successful surgery and achieved years of seizure freedom. The evaluation does not commit to surgery — it answers the question of whether surgery is an option. Call 040-44885000.

Not necessarily. Bilateral seizure onset on scalp EEG is not the same as truly bilateral epileptogenesis. In many patients, what appears bilateral on scalp EEG is a rapidly spreading unilateral focus. Phase 2 sEEG records directly from bilateral brain targets simultaneously and definitively determines whether seizures are truly bilateral in origin or simply spreading fast. At KIMS, a meaningful proportion of patients referred with “bilateral” onset are found on sEEG to have a unilateral focus that can be surgically addressed. The sEEG evaluation is the definitive answer — not the scalp EEG. Even for truly bilateral epilepsy, corpus callosotomy and neuromodulation (VNS, DBS) remain meaningful options. Call 040-44885000.

Age 55 is not a contraindication to epilepsy surgery. Surgical success rates are somewhat lower in older patients than younger patients, primarily because longer epilepsy duration allows secondary epileptogenesis to spread. However, the comparison is not surgery versus a perfect outcome — it is surgery versus another 10–20 years of uncontrolled seizures, medication side effects, and progressive cognitive decline. Many 55-year-old patients with temporal lobe epilepsy achieve excellent outcomes at KIMS. A 55-year-old with a clearly visible mesial temporal lesion on MRI and concordant EEG onset is a good surgical candidate regardless of age. Call 040-44885000.

The answer is: immediately. There should be no additional waiting period after two adequate drug trials have failed. The ILAE defines drug-resistant epilepsy at the point of two failed drug trials, and the clinical guidance at that point is to refer for surgical evaluation — not to try a third, fourth, or fifth medication first. Every additional year of uncontrolled seizures before evaluation adds progressive hippocampal atrophy, cognitive decline, and SUDEP risk. The average Indian patient waits 15–20 years before surgical evaluation; the evidence suggests outcomes are better the earlier surgery is performed. Two failed drugs is the trigger — not a waiting room. Call 040-44885000.

Lennox-Gastaut syndrome (LGS) is a severe epileptic encephalopathy and is not curable by resective surgery in most cases because the epilepsy is generalised rather than focal. However, the most dangerous seizures in LGS — atonic drop attacks causing sudden falls and repeated head injuries — respond well to corpus callosotomy. At KIMS, corpus callosotomy reduces drop attacks by 70–85% in LGS patients, often transforming a child who required a helmet and constant supervision into one who is significantly safer. For broader seizure reduction: VNS reduces overall seizure frequency by ≥50% in approximately 50% of LGS patients · the ketogenic diet achieves significant reduction in 50% · FDA-approved fenfluramine should be reviewed with the treating neurologist for LGS. KIMS evaluates each LGS patient individually. Call 040-44885000.

Starting from Vijayawada does not require an immediate trip to Hyderabad. Step 1: Gather and send existing records to KIMS — MRI discs (DICOM), all EEG reports, current medication list, seizure diary, referral letter. Email to neuroscience@kimshospitals.com with a brief clinical summary. Step 2: The KIMS epilepsy team reviews the records and advises by email or phone on urgency and next steps. Step 3: Book the initial consultation at 040-44885000 — ideally 2 days in Hyderabad to complete consultation and initial investigations. Step 4: If Phase 1 video-EEG monitoring is recommended, this is a 5–10 day admission, planned around school and work schedules where possible. Patients from Vijayawada, Guntur, and Nellore have been evaluated and treated at KIMS throughout the programme’s history. Call 040-44885000.

The single most important answer on this page: two failed drugs is the threshold for surgical referral, not ten. The evaluation does not commit a patient to surgery — it determines whether surgery is an option. That is worth one phone call to 040-44885000.

KIMS Neuroscience Epilepsy Programme

Two medications have failed. The seizures are still happening. The evaluation has not been done. At KIMS Hyderabad, epilepsy surgery, the complete evaluation pathway, and senior neurology and neurosurgery consultants are available. The evaluation — not the surgery, just the evaluation — is the first step. Call 040-44885000 · Email: neuroscience@kimshospitals.com

040-44885000

neuroscience@kimshospitals.com